<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00543309</url>
  </required_header>
  <id_info>
    <org_study_id>0735070N</org_study_id>
    <nct_id>NCT00543309</nct_id>
  </id_info>
  <brief_title>Effects of Perioperative Nesiritide or Milrinone Infusion on Recovery From Fontan Surgery</brief_title>
  <official_title>Impact of Empiric Nesiritide or Milrinone Infusion on Early Postoperative Recovery Following Fontan Surgery: a Randomized, Double-blind, Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John M Costello</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Childrenâ€™s Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The staged surgical pathway to treat children with single ventricle heart defects culminates
      with the Fontan operation. In this procedure, systemic venous return is rerouted directly to
      the pulmonary arteries, which serves to separate the systemic and pulmonary circulations.
      Although mortality following the Fontan operation is now uncommon, early postoperative
      morbidity including prolonged postoperative chest tube drainage and hospitalization remains
      significant. The efficacy of empiric inotropic, vasodilator and neurohumoral-inhibitory
      therapies in the perioperative period is unknown and practice varies widely between centers.

      The investigators will propose a single-center, randomized, double-blind, phase II clinical
      trial in children undergoing Fontan surgery. The investigators plan to compare the effects of
      perioperative nesiritide, milrinone and placebo infusions on the early postoperative clinical
      course and neurohumoral profile. The investigators hypothesize that, when compared to the
      milrinone and placebo groups, the nesiritide group will have more days alive and out of the
      hospital within the first 30 days after surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The staged surgical pathway to treat children with single ventricle heart defects culminates
      with the Fontan operation. In this procedure, systemic venous return is rerouted directly to
      the pulmonary arteries, which serves to separate the systemic and pulmonary circulations.
      Following this operation, deoxygenated blood flows passively from the body through the lungs
      without a pumping chamber. Although mortality following the Fontan operation is now uncommon,
      early postoperative morbidity including prolonged postoperative chest tube drainage and
      hospitalization remains significant. The efficacy of empiric inotropic, vasodilator and
      neurohumoral-inhibitory therapies in the perioperative period is unknown and practice varies
      widely between centers.

      We propose a single-center, randomized, double-blind, phase II clinical trial in children
      undergoing Fontan surgery. We plan to compare the effects of perioperative nesiritide,
      milrinone and placebo infusions on the early postoperative clinical course and neurohumoral
      profile. The primary aim of the study is to determine whether nesiritide, milrinone or
      placebo infusion is associated with fewer days alive and out of the hospital within 30 days
      of surgery. We hypothesize that, when compared to the milrinone and placebo groups, the
      nesiritide group will have more days alive and out of the hospital within the first 30 days
      after surgery. Secondary aims are to determine the effects of these infusions on
      postoperative resource consumption, hemodynamics, arrhythmias, renal function, neurohumoral
      activation and adverse events. Thirty-nine patients per group (117 total patients) will be
      enrolled over three years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    DSMB recommended termination based on interim outcomes analysis
  </why_stopped>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days Alive and Out of the Hospital Within 30 Days of Surgery.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular: Cardiac Index</measure>
    <time_frame>Postoperative hour #1</time_frame>
    <description>Cardiac index measured using Fick principle with measured oxygen consumption.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular: Cardiac Index</measure>
    <time_frame>Postoperative hour #8</time_frame>
    <description>Cardiac index measured using Fick principle with measured oxygen consumption.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular: Arrhythmia</measure>
    <time_frame>Postoperative day (POD) #0 through 5</time_frame>
    <description>arrhythmia lasting &gt;30 seconds or requiring treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular: Peak Inotrope Score</measure>
    <time_frame>Initial 24 hours in CICU</time_frame>
    <description>Peak Inotrope Score = Doses of dopamine in mcg/kg/minute + dobutamine in mcg/kg/minute + (epinephrine in mcg/kg/minute x 100).
The lowest (best) possible Peak Inotrope Score = 0 dose equivalents. There is no maximum Peak Inotrope Score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular: Peak Lactate Level</measure>
    <time_frame>Initial 24 hours in CICU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function: Urine Output</measure>
    <time_frame>first 24 hours CICU admit</time_frame>
    <description>Volume of urine in mL/kg per day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function: Maximum Change in Serum Creatinine</measure>
    <time_frame>14 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource Utilization: Hours of Mechanical Ventilation Until Initial Extubation</measure>
    <time_frame>From Fontan operation until initial extubation, assessed during initial CICU stay, up to 30 days.</time_frame>
    <description>Hours of mechanical ventilation until initial extubation following the Fontan operation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource Utilization: Days of Initial CICU Stay</measure>
    <time_frame>From Fontan operation until initial discharge from the CICU, assessed during the postoperative hospitalization, up to 90 days.</time_frame>
    <description>Days of initial postoperative CICU care following the Fontan operation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource Utilization: Chest Tube Days</measure>
    <time_frame>From Fontan operation until final chest tube removed, assessed during postoperative hospitalization, up to 90 days.</time_frame>
    <description>Days during which one or more chest tubes were in place following the Fontan operation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource Utilization: Days Alive and Out of Hospital Within 180 Days of Surgery</measure>
    <time_frame>180 days</time_frame>
    <description>Days the patient was alive and out of hospital within the 180 days after Fontan surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Norepinephrine Levels.</measure>
    <time_frame>Preoperative baseline to 24 hours after CICU admission</time_frame>
    <description>Plasma norepinephrine levels measured at preoperative baseline and postoperative CICU hour 1, 8, 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epinephrine Levels</measure>
    <time_frame>Preoperative baseline to 24 hours after CICU admission</time_frame>
    <description>Plasma epinephrine levels measured at preoperative baseline and postoperative CICU hour 1, 8, 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-terminal Pro-brain Natriuretic Peptide Levels</measure>
    <time_frame>Preoperative baseline to 24 hours after CICU admission</time_frame>
    <description>N-terminal pro-brain natriuretic peptide levels measured at preoperative baseline and postoperative CICU hour 1, 8, 24.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Heart Defects, Congenital</condition>
  <arm_group>
    <arm_group_label>I- nesiritide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to the nesiritide group will receive an intravenous loading dose of 2 mcg/kg followed by an infusion of 0.015 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II- Milrinone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients assigned to the milrinone group will receive a bolus of 50 mcg/kg followed by an infusion of 0.5 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>III- placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients assigned to the placebo group will receive a 0.33 mL/kg bolus of 5% dextrose in water (D5W), followed by an infusion of D5W, administered for at least 12 hours after CICU admission and up to five days, unless prespecified lack of efficacy criteria are met.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nesiritide</intervention_name>
    <description>Nesiritide bolus 2 mcg/kg on CPB, then infusion of 0.015 mcg/kg/min. infusion dose may be adjusted</description>
    <arm_group_label>I- nesiritide</arm_group_label>
    <other_name>Natrecor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>milrinone</intervention_name>
    <description>Milrinone 50 mcg/kg bolus on CPB, the infusion of 0.5 mcg/kg/min. Infusion rate may be adjusted</description>
    <arm_group_label>II- Milrinone</arm_group_label>
    <other_name>Primacor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo bolus on CPB, then placebo infusion</description>
    <arm_group_label>III- placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing an elective, primary Fontan operation at Children's Hospital
             Boston.

        Exclusion Criteria:

          -  Revision surgery for failing Fontan circulation.

          -  Preoperative serum creatinine &gt; 1.5 mg/dL or chronic dialysis.

          -  The attending surgeon, cardiac anesthesiologist, or cardiac intensivist has a
             compelling indication to initiate either nesiritide or milrinone outside of the
             confines of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John M Costello, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Childrenâ€™s Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Costello JM, Dunbar-Masterson C, Allan CK, Gauvreau K, Newburger JW, McGowan FX Jr, Wessel DL, Mayer JE Jr, Salvin JW, Dionne RE, Laussen PC. Impact of empiric nesiritide or milrinone infusion on early postoperative recovery after Fontan surgery: a randomized, double-blind, placebo-controlled trial. Circ Heart Fail. 2014 Jul;7(4):596-604. doi: 10.1161/CIRCHEARTFAILURE.113.001312. Epub 2014 Jun 6.</citation>
    <PMID>24906491</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>October 10, 2007</study_first_submitted>
  <study_first_submitted_qc>October 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2007</study_first_posted>
  <results_first_submitted>April 29, 2017</results_first_submitted>
  <results_first_submitted_qc>May 25, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 25, 2018</results_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Boston Childrenâ€™s Hospital</investigator_affiliation>
    <investigator_full_name>John M Costello</investigator_full_name>
    <investigator_title>Associate in Cardiology</investigator_title>
  </responsible_party>
  <keyword>Fontan Operation</keyword>
  <keyword>Cardiopulmonary Bypass</keyword>
  <keyword>Heart Defects, Congenital</keyword>
  <keyword>Milrinone</keyword>
  <keyword>Natriuretic peptide, brain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Milrinone</mesh_term>
    <mesh_term>Natriuretic Peptide, Brain</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>email the PI for data requests.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: October 2007 - January 2013.
Location: Cardiac operating rooms and cardiac intensive care unit (CICU) at Boston Children's Hospital</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>I- Nesiritide</title>
          <description>Patients assigned to the nesiritide group will receive an intravenous loading dose of 2 mcg/kg followed by an infusion of 0.015 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
nesiritide: Nesiritide bolus 2 mcg/kg on cardiopulmonary bypass (CPB), then infusion of 0.015 mcg/kg/min. infusion dose may be adjusted</description>
        </group>
        <group group_id="P2">
          <title>II- Milrinone</title>
          <description>Patients assigned to the milrinone group will receive a bolus of 50 mcg/kg followed by an infusion of 0.5 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
milrinone: Milrinone 50 mcg/kg bolus on CPB, the infusion of 0.5 mcg/kg/min. Infusion rate may be adjusted</description>
        </group>
        <group group_id="P3">
          <title>III- Placebo</title>
          <description>Patients assigned to the placebo group will receive a 0.33 mL/kg bolus of 5% dextrose in water (D5W), followed by an infusion of D5W, administered for at least 12 hours after CICU admission and up to five days, unless prespecified lack of efficacy criteria are met.
placebo: Placebo bolus on CPB, then placebo infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>I- Nesiritide</title>
          <description>Patients assigned to the nesiritide group will receive an intravenous loading dose of 2 mcg/kg followed by an infusion of 0.015 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
nesiritide: Nesiritide bolus 2 mcg/kg on CPB, then infusion of 0.015 mcg/kg/min. infusion dose may be adjusted</description>
        </group>
        <group group_id="B2">
          <title>II- Milrinone</title>
          <description>Patients assigned to the milrinone group will receive a bolus of 50 mcg/kg followed by an infusion of 0.5 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
milrinone: Milrinone 50 mcg/kg bolus on CPB, the infusion of 0.5 mcg/kg/min. Infusion rate may be adjusted</description>
        </group>
        <group group_id="B3">
          <title>III- Placebo</title>
          <description>Patients assigned to the placebo group will receive a 0.33 mL/kg bolus of 5% dextrose in water (D5W), followed by an infusion of D5W, administered for at least 12 hours after CICU admission and up to five days, unless prespecified lack of efficacy criteria are met.
placebo: Placebo bolus on CPB, then placebo infusion</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="35"/>
            <count group_id="B4" value="106"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.7" lower_limit="1.9" upper_limit="15.2"/>
                    <measurement group_id="B2" value="2.6" lower_limit="1.8" upper_limit="14.4"/>
                    <measurement group_id="B3" value="2.7" lower_limit="1.9" upper_limit="4.5"/>
                    <measurement group_id="B4" value="2.7" lower_limit="1.8" upper_limit="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic/Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.5" lower_limit="9.9" upper_limit="65.7"/>
                    <measurement group_id="B2" value="12.8" lower_limit="9.1" upper_limit="40.6"/>
                    <measurement group_id="B3" value="12.6" lower_limit="9.8" upper_limit="20.4"/>
                    <measurement group_id="B4" value="12.6" lower_limit="9.1" upper_limit="65.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ventricular Morphology</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Left dominant</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Right dominant</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Two ventricles</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Cardiac Operations</title>
          <units>operations</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="B2" value="2" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="B3" value="2" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="B4" value="2" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Interventional Cardiac Catheterization</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Arrhythmias</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Noncardiac congenital anomaly</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chromosomal abnormality or syndrome</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Days Alive and Out of the Hospital Within 30 Days of Surgery.</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>I- Nesiritide</title>
            <description>Patients assigned to the nesiritide group will receive an intravenous loading dose of 2 mcg/kg followed by an infusion of 0.015 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
nesiritide: Nesiritide bolus 2 mcg/kg on CPB, then infusion of 0.015 mcg/kg/min. infusion dose may be adjusted</description>
          </group>
          <group group_id="O2">
            <title>II- Milrinone</title>
            <description>Patients assigned to the milrinone group will receive a bolus of 50 mcg/kg followed by an infusion of 0.5 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
milrinone: Milrinone 50 mcg/kg bolus on CPB, the infusion of 0.5 mcg/kg/min. Infusion rate may be adjusted</description>
          </group>
          <group group_id="O3">
            <title>III- Placebo</title>
            <description>Patients assigned to the placebo group will receive a 0.33 mL/kg bolus of 5% dextrose in water (D5W), followed by an infusion of D5W, administered for at least 12 hours after CICU admission and up to five days, unless prespecified lack of efficacy criteria are met.
placebo: Placebo bolus on CPB, then placebo infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Days Alive and Out of the Hospital Within 30 Days of Surgery.</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="0" upper_limit="24"/>
                    <measurement group_id="O2" value="18" lower_limit="0" upper_limit="23"/>
                    <measurement group_id="O3" value="20" lower_limit="0" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiovascular: Cardiac Index</title>
        <description>Cardiac index measured using Fick principle with measured oxygen consumption.</description>
        <time_frame>Postoperative hour #1</time_frame>
        <population>Study patients for whom cardiac index measurements were available.</population>
        <group_list>
          <group group_id="O1">
            <title>I- Nesiritide</title>
            <description>Patients assigned to the nesiritide group will receive an intravenous loading dose of 2 mcg/kg followed by an infusion of 0.015 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
nesiritide: Nesiritide bolus 2 mcg/kg on CPB, then infusion of 0.015 mcg/kg/min. infusion dose may be adjusted</description>
          </group>
          <group group_id="O2">
            <title>II- Milrinone</title>
            <description>Patients assigned to the milrinone group will receive a bolus of 50 mcg/kg followed by an infusion of 0.5 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
milrinone: Milrinone 50 mcg/kg bolus on CPB, the infusion of 0.5 mcg/kg/min. Infusion rate may be adjusted</description>
          </group>
          <group group_id="O3">
            <title>III- Placebo</title>
            <description>Patients assigned to the placebo group will receive a 0.33 mL/kg bolus of 5% dextrose in water (D5W), followed by an infusion of D5W, administered for at least 12 hours after CICU admission and up to five days, unless prespecified lack of efficacy criteria are met.
placebo: Placebo bolus on CPB, then placebo infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiovascular: Cardiac Index</title>
          <description>Cardiac index measured using Fick principle with measured oxygen consumption.</description>
          <population>Study patients for whom cardiac index measurements were available.</population>
          <units>L/min/m2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="1.5" upper_limit="6.1"/>
                    <measurement group_id="O2" value="2.8" lower_limit="1.6" upper_limit="6.3"/>
                    <measurement group_id="O3" value="2.5" lower_limit="1.5" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiovascular: Cardiac Index</title>
        <description>Cardiac index measured using Fick principle with measured oxygen consumption.</description>
        <time_frame>Postoperative hour #8</time_frame>
        <population>Study patients for whom cardiac index measurements were available.</population>
        <group_list>
          <group group_id="O1">
            <title>I- Nesiritide</title>
            <description>Patients assigned to the nesiritide group will receive an intravenous loading dose of 2 mcg/kg followed by an infusion of 0.015 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
nesiritide: Nesiritide bolus 2 mcg/kg on CPB, then infusion of 0.015 mcg/kg/min. infusion dose may be adjusted</description>
          </group>
          <group group_id="O2">
            <title>II- Milrinone</title>
            <description>Patients assigned to the milrinone group will receive a bolus of 50 mcg/kg followed by an infusion of 0.5 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
milrinone: Milrinone 50 mcg/kg bolus on CPB, the infusion of 0.5 mcg/kg/min. Infusion rate may be adjusted</description>
          </group>
          <group group_id="O3">
            <title>III- Placebo</title>
            <description>Patients assigned to the placebo group will receive a 0.33 mL/kg bolus of 5% dextrose in water (D5W), followed by an infusion of D5W, administered for at least 12 hours after CICU admission and up to five days, unless prespecified lack of efficacy criteria are met.
placebo: Placebo bolus on CPB, then placebo infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiovascular: Cardiac Index</title>
          <description>Cardiac index measured using Fick principle with measured oxygen consumption.</description>
          <population>Study patients for whom cardiac index measurements were available.</population>
          <units>L/min/m2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="0.6" upper_limit="6.7"/>
                    <measurement group_id="O2" value="2.9" lower_limit="0.9" upper_limit="5.9"/>
                    <measurement group_id="O3" value="2.5" lower_limit="1.0" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiovascular: Arrhythmia</title>
        <description>arrhythmia lasting &gt;30 seconds or requiring treatment</description>
        <time_frame>Postoperative day (POD) #0 through 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>I- Nesiritide</title>
            <description>Patients assigned to the nesiritide group will receive an intravenous loading dose of 2 mcg/kg followed by an infusion of 0.015 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
nesiritide: Nesiritide bolus 2 mcg/kg on CPB, then infusion of 0.015 mcg/kg/min. infusion dose may be adjusted</description>
          </group>
          <group group_id="O2">
            <title>II- Milrinone</title>
            <description>Patients assigned to the milrinone group will receive a bolus of 50 mcg/kg followed by an infusion of 0.5 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
milrinone: Milrinone 50 mcg/kg bolus on CPB, the infusion of 0.5 mcg/kg/min. Infusion rate may be adjusted</description>
          </group>
          <group group_id="O3">
            <title>III- Placebo</title>
            <description>Patients assigned to the placebo group will receive a 0.33 mL/kg bolus of 5% dextrose in water (D5W), followed by an infusion of D5W, administered for at least 12 hours after CICU admission and up to five days, unless prespecified lack of efficacy criteria are met.
placebo: Placebo bolus on CPB, then placebo infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiovascular: Arrhythmia</title>
          <description>arrhythmia lasting &gt;30 seconds or requiring treatment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiovascular: Peak Inotrope Score</title>
        <description>Peak Inotrope Score = Doses of dopamine in mcg/kg/minute + dobutamine in mcg/kg/minute + (epinephrine in mcg/kg/minute x 100).
The lowest (best) possible Peak Inotrope Score = 0 dose equivalents. There is no maximum Peak Inotrope Score.</description>
        <time_frame>Initial 24 hours in CICU</time_frame>
        <group_list>
          <group group_id="O1">
            <title>I- Nesiritide</title>
            <description>Patients assigned to the nesiritide group will receive an intravenous loading dose of 2 mcg/kg followed by an infusion of 0.015 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
nesiritide: Nesiritide bolus 2 mcg/kg on CPB, then infusion of 0.015 mcg/kg/min. infusion dose may be adjusted</description>
          </group>
          <group group_id="O2">
            <title>II- Milrinone</title>
            <description>Patients assigned to the milrinone group will receive a bolus of 50 mcg/kg followed by an infusion of 0.5 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
milrinone: Milrinone 50 mcg/kg bolus on CPB, the infusion of 0.5 mcg/kg/min. Infusion rate may be adjusted</description>
          </group>
          <group group_id="O3">
            <title>III- Placebo</title>
            <description>Patients assigned to the placebo group will receive a 0.33 mL/kg bolus of 5% dextrose in water (D5W), followed by an infusion of D5W, administered for at least 12 hours after CICU admission and up to five days, unless prespecified lack of efficacy criteria are met.
placebo: Placebo bolus on CPB, then placebo infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiovascular: Peak Inotrope Score</title>
          <description>Peak Inotrope Score = Doses of dopamine in mcg/kg/minute + dobutamine in mcg/kg/minute + (epinephrine in mcg/kg/minute x 100).
The lowest (best) possible Peak Inotrope Score = 0 dose equivalents. There is no maximum Peak Inotrope Score.</description>
          <units>dose equivalents</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="0" upper_limit="15"/>
                    <measurement group_id="O2" value="5" lower_limit="0" upper_limit="16"/>
                    <measurement group_id="O3" value="5" lower_limit="0" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiovascular: Peak Lactate Level</title>
        <time_frame>Initial 24 hours in CICU</time_frame>
        <group_list>
          <group group_id="O1">
            <title>I- Nesiritide</title>
            <description>Patients assigned to the nesiritide group will receive an intravenous loading dose of 2 mcg/kg followed by an infusion of 0.015 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
nesiritide: Nesiritide bolus 2 mcg/kg on CPB, then infusion of 0.015 mcg/kg/min. infusion dose may be adjusted</description>
          </group>
          <group group_id="O2">
            <title>II- Milrinone</title>
            <description>Patients assigned to the milrinone group will receive a bolus of 50 mcg/kg followed by an infusion of 0.5 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
milrinone: Milrinone 50 mcg/kg bolus on CPB, the infusion of 0.5 mcg/kg/min. Infusion rate may be adjusted</description>
          </group>
          <group group_id="O3">
            <title>III- Placebo</title>
            <description>Patients assigned to the placebo group will receive a 0.33 mL/kg bolus of 5% dextrose in water (D5W), followed by an infusion of D5W, administered for at least 12 hours after CICU admission and up to five days, unless prespecified lack of efficacy criteria are met.
placebo: Placebo bolus on CPB, then placebo infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiovascular: Peak Lactate Level</title>
          <units>mEq/liter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="1.6" upper_limit="12.6"/>
                    <measurement group_id="O2" value="3.1" lower_limit="1.5" upper_limit="13.7"/>
                    <measurement group_id="O3" value="3.1" lower_limit="1.4" upper_limit="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Function: Urine Output</title>
        <description>Volume of urine in mL/kg per day</description>
        <time_frame>first 24 hours CICU admit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>I- Nesiritide</title>
            <description>Patients assigned to the nesiritide group will receive an intravenous loading dose of 2 mcg/kg followed by an infusion of 0.015 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
nesiritide: Nesiritide bolus 2 mcg/kg on CPB, then infusion of 0.015 mcg/kg/min. infusion dose may be adjusted</description>
          </group>
          <group group_id="O2">
            <title>II- Milrinone</title>
            <description>Patients assigned to the milrinone group will receive a bolus of 50 mcg/kg followed by an infusion of 0.5 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
milrinone: Milrinone 50 mcg/kg bolus on CPB, the infusion of 0.5 mcg/kg/min. Infusion rate may be adjusted</description>
          </group>
          <group group_id="O3">
            <title>III- Placebo</title>
            <description>Patients assigned to the placebo group will receive a 0.33 mL/kg bolus of 5% dextrose in water (D5W), followed by an infusion of D5W, administered for at least 12 hours after CICU admission and up to five days, unless prespecified lack of efficacy criteria are met.
placebo: Placebo bolus on CPB, then placebo infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Function: Urine Output</title>
          <description>Volume of urine in mL/kg per day</description>
          <units>mL/kg per day</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="13" upper_limit="87"/>
                    <measurement group_id="O2" value="37" lower_limit="13" upper_limit="94"/>
                    <measurement group_id="O3" value="34" lower_limit="15" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Function: Maximum Change in Serum Creatinine</title>
        <time_frame>14 days after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>I- Nesiritide</title>
            <description>Patients assigned to the nesiritide group will receive an intravenous loading dose of 2 mcg/kg followed by an infusion of 0.015 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
nesiritide: Nesiritide bolus 2 mcg/kg on CPB, then infusion of 0.015 mcg/kg/min. infusion dose may be adjusted</description>
          </group>
          <group group_id="O2">
            <title>II- Milrinone</title>
            <description>Patients assigned to the milrinone group will receive a bolus of 50 mcg/kg followed by an infusion of 0.5 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
milrinone: Milrinone 50 mcg/kg bolus on CPB, the infusion of 0.5 mcg/kg/min. Infusion rate may be adjusted</description>
          </group>
          <group group_id="O3">
            <title>III- Placebo</title>
            <description>Patients assigned to the placebo group will receive a 0.33 mL/kg bolus of 5% dextrose in water (D5W), followed by an infusion of D5W, administered for at least 12 hours after CICU admission and up to five days, unless prespecified lack of efficacy criteria are met.
placebo: Placebo bolus on CPB, then placebo infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Function: Maximum Change in Serum Creatinine</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0.0" upper_limit="4.8"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0.0" upper_limit="0.6"/>
                    <measurement group_id="O3" value="0.2" lower_limit="-0.1" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resource Utilization: Hours of Mechanical Ventilation Until Initial Extubation</title>
        <description>Hours of mechanical ventilation until initial extubation following the Fontan operation.</description>
        <time_frame>From Fontan operation until initial extubation, assessed during initial CICU stay, up to 30 days.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>I- Nesiritide</title>
            <description>Patients assigned to the nesiritide group will receive an intravenous loading dose of 2 mcg/kg followed by an infusion of 0.015 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
nesiritide: Nesiritide bolus 2 mcg/kg on CPB, then infusion of 0.015 mcg/kg/min. infusion dose may be adjusted</description>
          </group>
          <group group_id="O2">
            <title>II- Milrinone</title>
            <description>Patients assigned to the milrinone group will receive a bolus of 50 mcg/kg followed by an infusion of 0.5 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
milrinone: Milrinone 50 mcg/kg bolus on CPB, the infusion of 0.5 mcg/kg/min. Infusion rate may be adjusted</description>
          </group>
          <group group_id="O3">
            <title>III- Placebo</title>
            <description>Patients assigned to the placebo group will receive a 0.33 mL/kg bolus of 5% dextrose in water (D5W), followed by an infusion of D5W, administered for at least 12 hours after CICU admission and up to five days, unless prespecified lack of efficacy criteria are met.
placebo: Placebo bolus on CPB, then placebo infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Resource Utilization: Hours of Mechanical Ventilation Until Initial Extubation</title>
          <description>Hours of mechanical ventilation until initial extubation following the Fontan operation.</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="8" upper_limit="505"/>
                    <measurement group_id="O2" value="23" lower_limit="9" upper_limit="337"/>
                    <measurement group_id="O3" value="22" lower_limit="5" upper_limit="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resource Utilization: Days of Initial CICU Stay</title>
        <description>Days of initial postoperative CICU care following the Fontan operation.</description>
        <time_frame>From Fontan operation until initial discharge from the CICU, assessed during the postoperative hospitalization, up to 90 days.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>I- Nesiritide</title>
            <description>Patients assigned to the nesiritide group will receive an intravenous loading dose of 2 mcg/kg followed by an infusion of 0.015 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
nesiritide: Nesiritide bolus 2 mcg/kg on CPB, then infusion of 0.015 mcg/kg/min. infusion dose may be adjusted</description>
          </group>
          <group group_id="O2">
            <title>II- Milrinone</title>
            <description>Patients assigned to the milrinone group will receive a bolus of 50 mcg/kg followed by an infusion of 0.5 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
milrinone: Milrinone 50 mcg/kg bolus on CPB, the infusion of 0.5 mcg/kg/min. Infusion rate may be adjusted</description>
          </group>
          <group group_id="O3">
            <title>III- Placebo</title>
            <description>Patients assigned to the placebo group will receive a 0.33 mL/kg bolus of 5% dextrose in water (D5W), followed by an infusion of D5W, administered for at least 12 hours after CICU admission and up to five days, unless prespecified lack of efficacy criteria are met.
placebo: Placebo bolus on CPB, then placebo infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Resource Utilization: Days of Initial CICU Stay</title>
          <description>Days of initial postoperative CICU care following the Fontan operation.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="1" upper_limit="21"/>
                    <measurement group_id="O2" value="3" lower_limit="1" upper_limit="16"/>
                    <measurement group_id="O3" value="2" lower_limit="1" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resource Utilization: Chest Tube Days</title>
        <description>Days during which one or more chest tubes were in place following the Fontan operation.</description>
        <time_frame>From Fontan operation until final chest tube removed, assessed during postoperative hospitalization, up to 90 days.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>I- Nesiritide</title>
            <description>Patients assigned to the nesiritide group will receive an intravenous loading dose of 2 mcg/kg followed by an infusion of 0.015 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
nesiritide: Nesiritide bolus 2 mcg/kg on CPB, then infusion of 0.015 mcg/kg/min. infusion dose may be adjusted</description>
          </group>
          <group group_id="O2">
            <title>II- Milrinone</title>
            <description>Patients assigned to the milrinone group will receive a bolus of 50 mcg/kg followed by an infusion of 0.5 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
milrinone: Milrinone 50 mcg/kg bolus on CPB, the infusion of 0.5 mcg/kg/min. Infusion rate may be adjusted</description>
          </group>
          <group group_id="O3">
            <title>III- Placebo</title>
            <description>Patients assigned to the placebo group will receive a 0.33 mL/kg bolus of 5% dextrose in water (D5W), followed by an infusion of D5W, administered for at least 12 hours after CICU admission and up to five days, unless prespecified lack of efficacy criteria are met.
placebo: Placebo bolus on CPB, then placebo infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Resource Utilization: Chest Tube Days</title>
          <description>Days during which one or more chest tubes were in place following the Fontan operation.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="1" upper_limit="19"/>
                    <measurement group_id="O2" value="5" lower_limit="1" upper_limit="21"/>
                    <measurement group_id="O3" value="5" lower_limit="1" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resource Utilization: Days Alive and Out of Hospital Within 180 Days of Surgery</title>
        <description>Days the patient was alive and out of hospital within the 180 days after Fontan surgery</description>
        <time_frame>180 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>I- Nesiritide</title>
            <description>Patients assigned to the nesiritide group will receive an intravenous loading dose of 2 mcg/kg followed by an infusion of 0.015 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
nesiritide: Nesiritide bolus 2 mcg/kg on CPB, then infusion of 0.015 mcg/kg/min. infusion dose may be adjusted</description>
          </group>
          <group group_id="O2">
            <title>II- Milrinone</title>
            <description>Patients assigned to the milrinone group will receive a bolus of 50 mcg/kg followed by an infusion of 0.5 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
milrinone: Milrinone 50 mcg/kg bolus on CPB, the infusion of 0.5 mcg/kg/min. Infusion rate may be adjusted</description>
          </group>
          <group group_id="O3">
            <title>III- Placebo</title>
            <description>Patients assigned to the placebo group will receive a 0.33 mL/kg bolus of 5% dextrose in water (D5W), followed by an infusion of D5W, administered for at least 12 hours after CICU admission and up to five days, unless prespecified lack of efficacy criteria are met.
placebo: Placebo bolus on CPB, then placebo infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Resource Utilization: Days Alive and Out of Hospital Within 180 Days of Surgery</title>
          <description>Days the patient was alive and out of hospital within the 180 days after Fontan surgery</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167" lower_limit="0" upper_limit="174"/>
                    <measurement group_id="O2" value="168" lower_limit="102" upper_limit="173"/>
                    <measurement group_id="O3" value="170" lower_limit="30" upper_limit="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Norepinephrine Levels.</title>
        <description>Plasma norepinephrine levels measured at preoperative baseline and postoperative CICU hour 1, 8, 24.</description>
        <time_frame>Preoperative baseline to 24 hours after CICU admission</time_frame>
        <group_list>
          <group group_id="O1">
            <title>I- Nesiritide</title>
            <description>Patients assigned to the nesiritide group will receive an intravenous loading dose of 2 mcg/kg followed by an infusion of 0.015 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
nesiritide: Nesiritide bolus 2 mcg/kg on cardiopulmonary bypass (CPB), then infusion of 0.015 mcg/kg/min. infusion dose may be adjusted</description>
          </group>
          <group group_id="O2">
            <title>II- Milrinone</title>
            <description>Patients assigned to the milrinone group will receive a bolus of 50 mcg/kg followed by an infusion of 0.5 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
milrinone: Milrinone 50 mcg/kg bolus on CPB, the infusion of 0.5 mcg/kg/min. Infusion rate may be adjusted</description>
          </group>
          <group group_id="O3">
            <title>III- Placebo</title>
            <description>Patients assigned to the placebo group will receive a 0.33 mL/kg bolus of 5% dextrose in water (D5W), followed by an infusion of D5W, administered for at least 12 hours after CICU admission and up to five days, unless prespecified lack of efficacy criteria are met.
placebo: Placebo bolus on CPB, then placebo infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Norepinephrine Levels.</title>
          <description>Plasma norepinephrine levels measured at preoperative baseline and postoperative CICU hour 1, 8, 24.</description>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Preoperative baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.1" upper_limit="4.2"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.1" upper_limit="5.1"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.1" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour after CICU admit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.6" upper_limit="18.0"/>
                    <measurement group_id="O2" value="2.1" lower_limit="0.3" upper_limit="30.5"/>
                    <measurement group_id="O3" value="2.9" lower_limit="0.4" upper_limit="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours after CICU admit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="0.3" upper_limit="11.0"/>
                    <measurement group_id="O2" value="2.4" lower_limit="0.2" upper_limit="13.7"/>
                    <measurement group_id="O3" value="1.3" lower_limit="0.1" upper_limit="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours after CICU admit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.1" upper_limit="12.1"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0.2" upper_limit="14.5"/>
                    <measurement group_id="O3" value="1.3" lower_limit="0.1" upper_limit="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Epinephrine Levels</title>
        <description>Plasma epinephrine levels measured at preoperative baseline and postoperative CICU hour 1, 8, 24.</description>
        <time_frame>Preoperative baseline to 24 hours after CICU admission</time_frame>
        <group_list>
          <group group_id="O1">
            <title>I- Nesiritide</title>
            <description>Patients assigned to the nesiritide group will receive an intravenous loading dose of 2 mcg/kg followed by an infusion of 0.015 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
nesiritide: Nesiritide bolus 2 mcg/kg on cardiopulmonary bypass (CPB), then infusion of 0.015 mcg/kg/min. infusion dose may be adjusted</description>
          </group>
          <group group_id="O2">
            <title>II- Milrinone</title>
            <description>Patients assigned to the milrinone group will receive a bolus of 50 mcg/kg followed by an infusion of 0.5 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
milrinone: Milrinone 50 mcg/kg bolus on CPB, the infusion of 0.5 mcg/kg/min. Infusion rate may be adjusted</description>
          </group>
          <group group_id="O3">
            <title>III- Placebo</title>
            <description>Patients assigned to the placebo group will receive a 0.33 mL/kg bolus of 5% dextrose in water (D5W), followed by an infusion of D5W, administered for at least 12 hours after CICU admission and up to five days, unless prespecified lack of efficacy criteria are met.
placebo: Placebo bolus on CPB, then placebo infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Epinephrine Levels</title>
          <description>Plasma epinephrine levels measured at preoperative baseline and postoperative CICU hour 1, 8, 24.</description>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Preoperative baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0.1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="1.6"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour after CICU admit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0" upper_limit="6.2"/>
                    <measurement group_id="O2" value="2.7" lower_limit="0" upper_limit="14.7"/>
                    <measurement group_id="O3" value="2.1" lower_limit="0.1" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours after CICU admit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0" upper_limit="3.3"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0" upper_limit="6.9"/>
                    <measurement group_id="O3" value="1.0" lower_limit="0.1" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours after CICU admit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0" upper_limit="1.5"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0.2" upper_limit="14.5"/>
                    <measurement group_id="O3" value="1.3" lower_limit="0.1" upper_limit="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>N-terminal Pro-brain Natriuretic Peptide Levels</title>
        <description>N-terminal pro-brain natriuretic peptide levels measured at preoperative baseline and postoperative CICU hour 1, 8, 24.</description>
        <time_frame>Preoperative baseline to 24 hours after CICU admission</time_frame>
        <group_list>
          <group group_id="O1">
            <title>I- Nesiritide</title>
            <description>Patients assigned to the nesiritide group will receive an intravenous loading dose of 2 mcg/kg followed by an infusion of 0.015 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
nesiritide: Nesiritide bolus 2 mcg/kg on cardiopulmonary bypass (CPB), then infusion of 0.015 mcg/kg/min. infusion dose may be adjusted</description>
          </group>
          <group group_id="O2">
            <title>II- Milrinone</title>
            <description>Patients assigned to the milrinone group will receive a bolus of 50 mcg/kg followed by an infusion of 0.5 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
milrinone: Milrinone 50 mcg/kg bolus on CPB, the infusion of 0.5 mcg/kg/min. Infusion rate may be adjusted</description>
          </group>
          <group group_id="O3">
            <title>III- Placebo</title>
            <description>Patients assigned to the placebo group will receive a 0.33 mL/kg bolus of 5% dextrose in water (D5W), followed by an infusion of D5W, administered for at least 12 hours after CICU admission and up to five days, unless prespecified lack of efficacy criteria are met.
placebo: Placebo bolus on CPB, then placebo infusion</description>
          </group>
        </group_list>
        <measure>
          <title>N-terminal Pro-brain Natriuretic Peptide Levels</title>
          <description>N-terminal pro-brain natriuretic peptide levels measured at preoperative baseline and postoperative CICU hour 1, 8, 24.</description>
          <units>fmol/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Preoperative baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" lower_limit="25" upper_limit="742"/>
                    <measurement group_id="O2" value="77" lower_limit="40" upper_limit="154"/>
                    <measurement group_id="O3" value="88" lower_limit="33" upper_limit="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour after CICU admit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="15" upper_limit="383"/>
                    <measurement group_id="O2" value="61" lower_limit="27" upper_limit="142"/>
                    <measurement group_id="O3" value="77" lower_limit="27" upper_limit="417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours after CICU admit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="59" upper_limit="331"/>
                    <measurement group_id="O2" value="71" lower_limit="36" upper_limit="268"/>
                    <measurement group_id="O3" value="88" lower_limit="49" upper_limit="600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours after CICU admit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142" lower_limit="61" upper_limit="412"/>
                    <measurement group_id="O2" value="136" lower_limit="44" upper_limit="518"/>
                    <measurement group_id="O3" value="109" lower_limit="67" upper_limit="570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>I- Nesiritide</title>
          <description>Patients assigned to the nesiritide group will receive an intravenous loading dose of 2 mcg/kg followed by an infusion of 0.015 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
nesiritide: Nesiritide bolus 2 mcg/kg on CPB, then infusion of 0.015 mcg/kg/min. infusion dose may be adjusted</description>
        </group>
        <group group_id="E2">
          <title>II- Milrinone</title>
          <description>Patients assigned to the milrinone group will receive a bolus of 50 mcg/kg followed by an infusion of 0.5 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
milrinone: Milrinone 50 mcg/kg bolus on CPB, the infusion of 0.5 mcg/kg/min. Infusion rate may be adjusted</description>
        </group>
        <group group_id="E3">
          <title>III- Placebo</title>
          <description>Patients assigned to the placebo group will receive a 0.33 mL/kg bolus of 5% dextrose in water (D5W), followed by an infusion of D5W, administered for at least 12 hours after CICU admission and up to five days, unless prespecified lack of efficacy criteria are met.
placebo: Placebo bolus on CPB, then placebo infusion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal insufficiency</sub_title>
                <description>&gt;= three-fold increase in serum creatinine c/w baseline or dialysis</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Single center design limits generalizability of findings. Study drug doses were extrapolated from published experience in other patient types. Study may have been underpowered to detect differences among treatment groups for secondary outcomes.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>John M. Costello, M.D., M.P.H.</name_or_title>
      <organization>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</organization>
      <phone>312 227 1551</phone>
      <email>jmcostello@luriechildrens.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

